 LEEDS, England--BUSINESS WIRE--4D pharma plc AIM: DDD, NASDAQ: LBPS, a pharmaceutical company leading the development of Live Biotherapeutic products LBPs, a novel class of drug derived from the microbiome, today announces new biomarker analyses from two ongoing clinical trials of its lead immuno-oncology single strain Live Biotherapeutic, MRx0518, in both neoadjuvant and refractory solid tumor settings, at the European Society for Medical Oncology ESMO Congress, September 16-21, 2021. 